Wat is de prijs voor CohBar, Inc. (CWBR)

Het prijs van CohBar, Inc. (CWBR) is $0.41

Wat is de marktkapitalisatie voor CohBar, Inc. (CWBR)

Marktkapitalisatie voorCohBar, Inc. (CWBR) is $1.08M

CohBar, Inc. (CWBR) Uitstaande Aandelen

CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.

Jaar	Uitstaande aandelen	Wijzigen
2026 (TTM)	2.91M	0.31%
2022	2.90M	30.54%
2021	2.22M	36.45%
2020	1.63M	14.02%
2019	1.43M	3.78%
2018	1.38M	10.09%
2017	1.25M	13.13%
2016	1.10M	3.37%
2015	1.07M	80.48%
2014	591.75K	37.62%
2013	430.00K	6.70%
2012	403.00K	0.00%

Jaar

Uitstaande aandelen

Wijzigen

2026 (TTM)

2.91M

0.31%

2022

2.90M

30.54%

2021

2.22M

36.45%

2020

1.63M

14.02%

2019

1.43M

3.78%

2018

1.38M

10.09%

2017

1.25M

13.13%

2016

1.10M

3.37%

2015

1.07M

80.48%

2014

591.75K

37.62%

2013

430.00K

6.70%

2012

403.00K

0.00%

Bedrijf	Uitstaande aandelen	Verschil	Land
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	8,634.31%	US
Argenx SE ARGX.US	62.19M	2,039.22%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	0.00	-100.00%	BE

Bedrijf

Uitstaande aandelen

Verschil

Land